FarmaSino was recommended by the China Chamber of Commerce for Import and Export of Medicines and Health Products and won the "Export Commodity Brand Certificate" issued by the Commercial Certification Center of the China Council for the Promotion of International Trade!

In order to cooperate with the implementation of the national brand strategy and standardization strategy, the China Chamber of Commerce for Import and Export of Medicines and Health Products and the Commercial Certification Center of the China Council for the Promotion of International Trade have established a linkage certification mechanism to promote "export commodity brand evaluation" in the medical and health field, and issue the "CCPIT Export Commodity Brand Certificate" for goods that meet brand standards to help enterprises build export brands. Its legality and effectiveness are accepted by governments, customs, chambers of commerce and enterprises in more than 200 countries and regions in the world, and have wide overseas recognition!

Winning this honor is a full recognition of the brand value of FarmaSino! Adhering to the corporate vision of "professional, dedicated and dedicated to doing a good job in health", FarmaSino will take this opportunity to accelerate the pace of international brand building and show the Chinese image and Chinese brand to the world!

THE

END

FarmaSino Co., Ltd. is a member of Jiangsu Huihong International Group (stock code: 600981), one of the top 500 companies in China, mainly engaged in the internationalization of biomedicine, and its products are sold in more than 120 countries and regions around the world. With an annual export volume of more than 200 million US dollars and annual sales of nearly 1.5 billion yuan, the company has been awarded the "Top 10 Export Enterprises of Western Patent Medicine" by the China Medical Insurance Chamber of Commerce for 9 consecutive years and among the "Top 100 Chinese Pharmaceutical Internationalization Enterprises" for 6 consecutive years. In 2017, the company was successfully elected as the vice president unit of China Chamber of Commerce for Import and Export of Medicines and Health Products. With high-quality products, advanced technology and high-end services, New Century Pharmaceutical makes unremitting efforts to promote the development of China's pharmaceutical industry and build an international biopharmaceutical enterprise integrating R&D, production and international trade.

FarmaSino Co., Ltd. is a wholly-owned subsidiary of FarmaSino Co., Ltd., providing one-stop technical services for the R&D and registration of generic drugs and innovative drugs, establishing industry-university-research cooperation with many universities and scientific research units such as China Pharmaceutical University and Nanjing University of Chinese Medicine, and reaching strategic cooperation with Sinopharm Group, Guangzhou Pharmaceutical Group, Guobang Pharmaceutical Group, Dingtai Pharmaceutical Research Group, etc. In 2021, the company obtained the B certificate of "Drug Manufacturing License" as a marketing authorization holder (MAH). The company has won the national "high-tech enterprise" certification, CNAS laboratory accreditation, national intellectual property management system certification, established Jiangsu Province enterprise graduate workstation, and won the honorary titles of Jiangsu Top 100 Science and Technology Service Institutions, Nanjing Engineering Technology Research Center for Consistency Evaluation of Generic Drugs, Nanjing Engineering Research Center, Nanjing Credit Management Demonstration Enterprise and so on.